{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:16:47Z","timestamp":1787062607615,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3584-9","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T09:09:17Z","timestamp":1544692157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies"],"prefix":"10.1186","volume":"18","author":[{"given":"Rita Wilson","family":"Dib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray Y.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Chaftari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"Raad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"issue":"11","key":"3584_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3324\/haematol.2011.044636","volume":"96","author":"MC Nicolle","year":"2011","unstructured":"Nicolle MC, Benet T, Thiebaut A, Bienvenu AL, Voirin N, Duclos A, Sobh M, Cannas G, Thomas X, Nicolini FE, et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica. 2011;96(11):1685\u201391.","journal-title":"Haematologica"},{"issue":"8","key":"3584_CR2","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068\u201375.","journal-title":"Haematologica"},{"issue":"8","key":"3584_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091\u2013100.","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"3584_CR4","doi-asserted-by":"publisher","first-page":"ii23","DOI":"10.1093\/jac\/dkw393","volume":"71","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Blennow O, Duarte RF, Munoz P. The current management landscape: aspergillosis. J Antimicrob Chemother. 2016;71(suppl 2):ii23\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3584_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3324\/haematol.2012.061952","volume":"97","author":"JA Maertens","year":"2012","unstructured":"Maertens JA, Nucci M, Donnelly JP. The role of antifungal treatment in hematology. Haematologica. 2012;97(3):325\u20137.","journal-title":"Haematologica"},{"key":"3584_CR6","first-page":"CD007394","volume":"12","author":"MM Leeflang","year":"2015","unstructured":"Leeflang MM, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Zhang M, Bossuyt PM, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015;12:CD007394.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"3584_CR7","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1086\/429921","volume":"40","author":"KA Marr","year":"2005","unstructured":"Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762\u20139.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3584_CR8","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/cncr.21755","volume":"106","author":"R Hachem","year":"2006","unstructured":"Hachem R, Sumoza D, Hanna H, Girgawy E, Munsell M, Raad I. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer\/mycosis study group (EORTC\/MSG) criteria be revised? Cancer. 2006;106(7):1581\u20136.","journal-title":"Cancer"},{"issue":"3","key":"3584_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1086\/509917","volume":"44","author":"RE Greene","year":"2007","unstructured":"Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3):373\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3584_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, et al. Practice guidelines for the diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u2013e60.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3584_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw De","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3584_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3904\/kjim.2015.30.6.899","volume":"30","author":"Y Okuturlar","year":"2015","unstructured":"Okuturlar Y, Ozkalemkas F, Ener B, Serin SO, Kazak E, Ozcelik T, Ozkocaman V, Ozkan HA, Akalin H, Gunaldi M, et al. Serum galactomannan levels in the diagnosis of invasive aspergillosis. Korean J Intern Med. 2015;30(6):899\u2013905.","journal-title":"Korean J Intern Med"},{"issue":"4","key":"3584_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1128\/JCM.06423-11","volume":"50","author":"J D'Haese","year":"2012","unstructured":"D'Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L, Meersseman P, Meersseman W, Lagrou K, Maertens J. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol. 2012;50(4):1258\u201363.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"3584_CR14","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1086\/597395","volume":"48","author":"C Cordonnier","year":"2009","unstructured":"Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhedin N, Isnard F, Ades L, Kuhnowski F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8):1042\u201351.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3584_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","volume":"72","author":"PA Pizzo","year":"1982","unstructured":"Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72(1):101\u201311.","journal-title":"Am J Med"},{"issue":"4","key":"3584_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JAH, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with Cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427\u201331.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3584_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3324\/haematol.2011.049999","volume":"97","author":"M Aguilar-Guisado","year":"2012","unstructured":"Aguilar-Guisado M, Mart\u00edn-Pe\u00f1a A, Espigado I, Ruiz P\u00e9rez de Pipaon M, Falantes J, de la Cruz F, Cisneros JM. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica. 2012;97(3):464\u201371.","journal-title":"Haematologica"},{"issue":"1","key":"3584_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2008.427","volume":"44","author":"FL Dignan","year":"2009","unstructured":"Dignan FL, Evans SO, Ethell ME, Shaw BE, Davies FE, Dearden CE, Treleaven JG, Riley UBG, Morgan GJ, Potter MN. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transpl. 2009;44(1):51\u20136.","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"3584_CR19","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1086\/496927","volume":"41","author":"J Maertens","year":"2005","unstructured":"Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J. Galactomannan and computed tomography - based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242\u201350.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3584_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(13)70076-8","volume":"13","author":"CO Morrissey","year":"2013","unstructured":"Morrissey CO, Chen SCA, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13(6):519\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"3584_CR21","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/j.ijid.2011.01.011","volume":"15","author":"BH Tan","year":"2011","unstructured":"Tan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, Goh YT, Wong GC. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis. 2011;15(5):e350\u20136.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"3584_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2009.21.8032","volume":"28","author":"C Girmenia","year":"2010","unstructured":"Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, Capria S, Minotti C, Cartoni C, Brocchieri S, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28(4):667\u201374.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3584_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1634\/theoncologist.2010-0290","volume":"16","author":"ER Ramos","year":"2011","unstructured":"Ramos ER, Jiang Y, Hachem R, Kassis C, Kontoyiannis DP, Raad I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist. 2011;16(7):1049\u201360.","journal-title":"Oncologist"},{"issue":"3","key":"3584_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","volume":"45","author":"II Raad","year":"2015","unstructured":"Raad II, El Zakhem A, El Helou G, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Ag. 2015;45(3):283\u20138.","journal-title":"Int J Antimicrob Ag"},{"issue":"6","key":"3584_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"3584_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/cid\/ciu911","volume":"60","author":"R Herbrecht","year":"2015","unstructured":"Herbrecht R, Patterson TF, Slavin MA, Marchetti O, Maertens J, Johnson EM, Schlamm HT, Donnelly JP, Pappas PG. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the mycoses study group (MSG 05) and the European Organization for Research and Treatment of Cancer infectious diseases group. Clin Infect Dis. 2015;60(5):713\u201320.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3584_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1473-3099(04)01045-X","volume":"4","author":"MA Mennink-Kersten","year":"2004","unstructured":"Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4(6):349\u201357.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 6","key":"3584_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/1469-0691.12513","volume":"20","author":"MC Arendrup","year":"2014","unstructured":"Arendrup MC. Update on antifungal resistance in aspergillus and Candida. Clin Microbiol Infect. 2014;20(Suppl 6):42\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"3584_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40265-017-0714-4","volume":"77","author":"R Garcia-Rubio","year":"2017","unstructured":"Garcia-Rubio R, Cuenca-Estrella M, Mellado E. Triazole resistance in aspergillus species: an emerging problem. Drugs. 2017;77(6):599\u2013613.","journal-title":"Drugs"},{"issue":"11","key":"3584_CR30","doi-asserted-by":"publisher","first-page":"e0140930","DOI":"10.1371\/journal.pone.0140930","volume":"10","author":"M Fung","year":"2015","unstructured":"Fung M, Kim J, Marty FM, Schwarzinger M, Koo S. Meta-analysis and cost comparison of empirical versus pre-Emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia. PLoS One. 2015;10(11):e0140930.","journal-title":"PLoS One"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3584-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T19:09:25Z","timestamp":1576177765000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3584-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3584"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3584-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"5 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The MD Anderson Cancer Center Institutional Review Board has reviewed and approved this retrospective study and a waiver of informed consent was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. IR is a consultant and speaker with Pfizer.IR, A-MC and RH are recipients of Pfizer study grants over the last 5\u2009years.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"656"}}